Personal information

Emails & domains

Verified email domains

Websites & social links

UCL IRIS Profile

Other IDs

ResearcherID: M-8353-2014

Activities

Collapse all

Employment (1)

University College London: London, England, GB

Employment
Source: check_circle
University College London

Works (26)

Controversies in the organization and structure of management for rare tumors

International Journal of Gynecological Cancer
2025-03 | Journal article
DOI: 10.1016/j.ijgc.2025.101669
Contributors: Isabelle Ray-Coquard; Jonathan Ledermann; Anna DeFazio; Aikou Okamoto; David Gershenson
Source: check_circle
Crossref

How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes

International Journal of Gynecological Cancer
2024-12 | Journal article
DOI: 10.1136/ijgc-2024-005976
Contributors: Lucy Haggstrom; Yeh Chen Lee; Clare Scott; Philipp Harter; Linn Woelber; Jonathan Ledermann; Charlie Gourley; Iain A McNeish; Frédéric Amant; Isabelle Ray-Coquard et al.
Source: check_circle
Crossref

Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London

Cancers
2024-10-24 | Journal article
DOI: 10.3390/cancers16213590
Contributors: Karim H. El-Shakankery; Joanna Kefas; Kieran Palmer; Andrew Houston; Uma Mukherjee; Kangbo Gao; Weiteen Tan; Shanthini M. Crusz; Michael J. Flynn; Jonathan A. Ledermann et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population

International Journal of Gynecologic Cancer
2024-09-03 | Journal article
DOI: 10.1136/ijgc-2024-005394
Contributors: Eve Merry; Ronas Taner Kesmez; Tamara Yu; Michael Flynn; Jonathan Ledermann; Michelle Lockley; Nicola Macdonald; Mary McCormack; Shibani Nicum; Shanthini Crusz et al.
Source: check_circle
Crossref

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor

Journal of Clinical Oncology
2024-04-10 | Journal article
DOI: 10.1200/JCO.23.01182
Contributors: Angelina Tjokrowidjaja; M.L. Friedlander; Jonathan A. Ledermann; Robert L. Coleman; Mansoor R. Mirza; Ursula A. Matulonis; Eric Pujade-Lauraine; Sarah J. Lord; Clare L. Scott; Sandra Goble et al.
Source: check_circle
Crossref

Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and intervention

Leukemia
2024-01 | Journal article
DOI: 10.1038/s41375-023-02040-6
Contributors: Ellen Nuttall Musson; Rowan E. Miller; Marc R. Mansour; Michelle Lockley; Jonathan A. Ledermann; Elspeth M. Payne
Source: check_circle
Crossref

An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app

International Journal of Gynecological Cancer
2023-08 | Journal article
DOI: 10.1136/ijgc-2023-004598
Contributors: Thomas Gaillard; Richard Schwameis; Enora Laas-Faron; Tali Eisenberg-Nissim; Xavier Matias-Guiu; Carien L. Creutzberg; Jonathan Ledermann; François Planchamp; Nicole Concin
Source: check_circle
Crossref

CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer

International Journal of Gynecological Cancer
2023-08 | Journal article
DOI: 10.1136/ijgc-2023-004308
Contributors: Ingrid Boere; Ignace Vergote; Rob Hanssen; Mathilde Jalving; Christine Gennigens; Petronella Ottevanger; Yes J. van de Wouw; Cristianne J.F. Rijcken; Ron H.J. Mathijssen; Jonathan Ledermann
Source: check_circle
Crossref

Evaluating open access publication and research impact in gynecologic oncology

International Journal of Gynecological Cancer
2023-07 | Journal article
DOI: 10.1136/ijgc-2023-004460
Contributors: Gabriel Levin; Ross Harrison; Jonathan Ledermann; Raanan Meyer; Robert L Coleman; Pedro T Ramirez
Source: check_circle
Crossref

Best original research presented at the 23rd European Congress on Gynaecological Oncology—Best of ESGO 2022

International Journal of Gynecological Cancer
2023-02 | Journal article
DOI: 10.1136/ijgc-2022-004184
Contributors: Joanna Kacperczyk-Bartnik; Nicolò Bizzarri; Martina Aida Angeles; Charalampos Theofanakis; Alexander B Shushkevich; Aleksandra Natalia Strojna; Andrei Pletnev; Tanja Nikolova; Jonathan Ledermann; Ignace Vergote
Source: check_circle
Crossref

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors

OncoTargets and Therapy
2022-10 | Journal article
DOI: 10.2147/OTT.S272199
Contributors: Rowan E Miller; Osnat Elyashiv; Karim H El-Shakankery; Jonathan A Ledermann
Source: check_circle
Crossref

The path for medical associations to sponsor trustworthy guidelines: is it feasible?

Journal of the Royal Society of Medicine
2022-07 | Journal article
DOI: 10.1177/01410768221095240
Contributors: Domenico Pagano; Philip Home; Alar Irs; Jonathan Ledermann; Giuseppe Curigliano; Tsuguo Iwatani; John Mandrola; Nick Freemantle
Source: check_circle
Crossref

Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer

Best Practice & Research Clinical Obstetrics & Gynaecology
2022-01 | Journal article
DOI: 10.1016/j.bpobgyn.2021.09.002
Contributors: Georgina E. Wood; Jonathan A. Ledermann
Source: check_circle
Crossref

British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic

International Journal of Gynecological Cancer
2022-01 | Journal article
DOI: 10.1136/ijgc-2021-002942
Contributors: Alexandra Taylor; Sudha S Sundar; Rebecca Bowen; Rick Clayton; Sarah Coleridge; Christina Fotopoulou; Sadaf Ghaem-Maghami; Jonathan Ledermann; Ranjit Manchanda; Hilary Maxwell et al.
Source: check_circle
Crossref

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

European Journal of Cancer
2021-09 | Journal article
DOI: 10.1016/j.ejca.2021.06.024
Contributors: Angelina Tjokrowidjaja; Michael Friedlander; Sarah J. Lord; Rebecca Asher; Manuel Rodrigues; Jonathan A. Ledermann; Ursula A. Matulonis; Amit M. Oza; Ilan Bruchim; Tomasz Huzarski et al.
Source: check_circle
Crossref

Frontline Maintenance Treatment for Ovarian Cancer

Current Oncology Reports
2021-08 | Journal article
DOI: 10.1007/s11912-021-01088-w
Contributors: Osnat Elyashiv; Yien Ning Sophia Wong; Jonathan A. Ledermann
Source: check_circle
Crossref

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

International Journal of Gynecological Cancer
2021-01 | Journal article
DOI: 10.1136/ijgc-2020-002230
Contributors: Nicole Concin; Xavier Matias-Guiu; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti et al.
Source: check_circle
Crossref

ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

International Journal of Gynecological Cancer
2021-01 | Journal article
DOI: 10.1136/ijgc-2020-002073
Contributors: Osnat Elyashiv; Jonathan Ledermann; Gita Parmar; Laura Farrelly; Nicholas Counsell; Amanda Feeney; Fatima El-Khouly; Ian Macdonald; Andreia Neto; Esther Arthur-Darkwa et al.
Source: check_circle
Crossref

Immune checkpoint inhibitors in ovarian cancer: where do we stand?

Therapeutic Advances in Medical Oncology
2021-01 | Journal article
DOI: 10.1177/17588359211039899
Contributors: Alexandra Leary; David Tan; Jonathan Ledermann
Source: check_circle
Crossref

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

Gynecologic Oncology
2019-01 | Journal article
DOI: 10.1016/j.ygyno.2018.08.036
Contributors: Antonio González Martín; Amit M. Oza; Andrew C. Embleton; Jacobus Pfisterer; Jonathan A. Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Monique A. Bertrand; Philip Beale; Andrés Cervantes et al.
Source: check_circle
Crossref

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer

Therapeutic Advances in Medical Oncology
2019-01 | Journal article
DOI: 10.1177/1758835919849753
Contributors: Jonathan A. Ledermann; Eric Pujade-Lauraine
Source: check_circle
Crossref

First-line treatment of ovarian cancer: questions and controversies to address

Therapeutic Advances in Medical Oncology
2018-01-01 | Journal article
DOI: 10.1177/1758835918768232
Contributors: Jonathan A. Ledermann
Source: check_circle
Crossref

Targeted Therapies for Ovarian Cancer

Best Practice & Research Clinical Obstetrics & Gynaecology
2017-05 | Journal article
DOI: 10.1016/j.bpobgyn.2016.12.001
Contributors: Tami Grunewald; Jonathan A. Ledermann
Source: check_circle
Crossref

Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review

Gynecologic Oncology
2017-01 | Journal article
DOI: 10.1016/j.ygyno.2016.11.001
Contributors: Claudia Marchetti; Rebecca Kristeleit; Mary McCormack; Tim Mould; Adeola Olaitan; Martin Widschwendter; Nicola MacDonald; Jonathan A Ledermann
Source: check_circle
Crossref

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease

Gynecologic Oncology Reports
2016-11 | Journal article
DOI: 10.1016/j.gore.2016.10.004
Contributors: Madeleine Bangham; Robert Goldstein; Henry Walton; Jonathan A Ledermann
Source: check_circle
Crossref

Homologous recombination deficiency and ovarian cancer

European Journal of Cancer
2016-06 | Journal article
DOI: 10.1016/j.ejca.2016.03.005
Contributors: Jonathan A. Ledermann; Yvette Drew; Rebecca S. Kristeleit
Source: check_circle
Crossref

Peer review (15 reviews for 6 publications/grants)

Review activity for Critical reviews in oncology/hematology. (2)
Review activity for Gynecologic oncology. (9)
Review activity for Nature reviews. (1)
Review activity for The lancet oncology. (1)
Review activity for The lancet. (1)
Review activity for The oncologist. (1)
How many people are using ORCID?